Veracyte's 20% Growth Is Real-Prosigna and TrueMRD Decide If It Becomes a 20% Story

Veracyte's current growth is already validated

Veracyte's first-quarter results were strong enough to settle the easy question: the company is still growing meaningfully. It posted 21% total revenue growth, while testing revenue rose 26%. That core momentum comes from Decipher and Afirma, not from future product hope.

That is why the stock debate now focuses on valuation rather than survival. Investors who like recency want to assume the next few years will keep looking like the last year. More cautious investors want product launches and expanded indications to prove the growth can broaden before they pay up.

Why the bull case has substance

The base business is helping, not hurting, the story. Management said Decipher and Afirma volume growth surpassed expectations and exceeded profitability targets. It also said the company believes it is approaching an inflection point with the upcoming launches of Prosigna LDT and TrueMRD.

If that framing proves right, Veracyte starts to look less like a steady diagnostic platform and more like a broader oncology growth story.

Why the bear case still matters

The cautious view is simpler: launches can extend momentum without immediately changing the multiple. Even so, the current quarter already raised the bar. The real question is no longer whether Veracyte is growing; it is whether Prosigna and TrueMRD can turn solid execution into a durable higher-growth narrative.